Q-omics provides the consensus-scored TRDC profile across patient tissues and cancer cell-line models. TRDC expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, TRDC is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, TRDC RNA expression shows 14,824 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight HNSC, KIRC, and UVM as cancer lineages where TRDC shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRDC — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRDC survival associations across molecular data types. TRDC RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRDC RNA expression–survival associations across cancer types. High TRDC expression shows unfavorable associations in KIRP, but favorable associations in HNSC, SKCM, DLBC, BRCA and ACC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for TRDC RNA expression.
This table summarizes TRDC tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TRDC. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRDC shows lower tumor expression in COAD, LUAD, LUSC and BRCA and higher tumor expression in KIRC and THCA. The KIRC box plot shows higher TRDC RNA expression in tumor versus normal tissue (log2 FC = +1.906, t-test p < 0.001).
This table shows molecular features associated with TRDC in patient tissues and cancer cell lines. In patient samples, TRDC shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
